Merck, Illumina and Genea form the Global Fertility Alliance

8 June 2015

Merck Serono, the biopharmaceutical business of Germany’s Merck KGaA (MRK: DE), today announced the formation of the Global Fertility Alliance, a new collaboration to advance excellence in fertility technologies and processes within the assisted reproductive treatment (ART) laboratory.

The alliance is a partnership between Merck Serono, US gene specialist Illumina (Nasdaq: ILMN) and Australian company Genea Limited, which develops innovative fertility technologies.

The alliance plans to introduce global standards in fertility technologies and protocols in ART labs as currently variation in practices and techniques can lead to inconsistent results and outcomes. The alliance aims to improve the consistency in ART worldwide and addresses the need for more standardization within the ART laboratory.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK